A share price of Regenxbio Inc [RGNX] is currently trading at $22.75, down -2.07%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The RGNX shares have gain 7.36% over the last week, with a monthly amount glided 56.14%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 6, March 2024, REGENXBIO Announces Pricing of Upsized Public Offering of Common Stock and Pre-funded Warrants. In a post published today on Yahoo Finance, REGENXBIO Inc. (Nasdaq: RGNX) a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy, today announced the pricing of an underwritten upsized public offering of 4,565,260 shares of its common stock at the price of $23.00 per share and 1,521,740 pre-funded warrants at a price of $22.9999 per warrant, in each case before underwriting discounts and commissions. The gross proceeds to REGENXBIO from the offering, before deducting the underwriting discounts and commissions and other offering expenses payable by REGENXBIO, are expected to be approximately $140.0 million. This offering is expected to close on March 11, 2024, subject to customary closing conditions. In addition, REGENXBIO has granted the underwriters a 30-day option to purchase an additional 913,050 shares of common stock at the public offering price, less underwriting discounts and commissions.
From an analyst’s perspective:
Regenxbio Inc [NASDAQ: RGNX] stock has seen the most recent analyst activity on March 08, 2024, when RBC Capital Mkts upgraded its rating to a Outperform and also boosted its price target to $35 from $20. Previously, Leerink Partners upgraded its rating to Outperform on March 06, 2024, and kept the price target unchanged to $37. Stifel started tracking the stock assigning a Buy rating and suggested a price target of $35 on November 01, 2023. Robert W. Baird initiated its recommendation with a Outperform and recommended $42 as its price target on June 02, 2023. Berenberg started tracking with a Buy rating for this stock on June 23, 2022, and assigned it a price target of $61. In a note dated December 15, 2021, Wedbush initiated an Neutral rating and provided a target price of $29 on this stock.
Regenxbio Inc experienced fluctuations in its stock price throughout the past year between $11.83 and $28.80. Regenxbio Inc [NASDAQ: RGNX] shares were valued at $22.75 at the most recent close of the market.
Analyzing the RGNX fundamentals
Trailing Twelve Months sales for Regenxbio Inc [NASDAQ:RGNX] were 90.24M which represents -29.13% decline. Gross Profit Margin for this corporation currently stands at 0.54% with Operating Profit Margin at -2.97%, Pretax Profit Margin comes in at -2.92%, and Net Profit Margin reading is -2.96%. To continue investigating profitability, this company’s Return on Assets is posted at -0.46, Equity is -0.69 and Total Capital is -0.6. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.29.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 21.95 points at the first support level, and at 21.14 for the second support level. However, for the 1st resistance point, the stock is sitting at 23.91, and for the 2nd resistance point, it is at 25.06.
Regenxbio Inc [RGNX] reported earnings per share of -$1.43 for its fiscal quarter that ended on 12/30/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$1.27/share, meaning a difference of -$0.16 and a surprise factor of -12.60%. By comparison, the stated earnings for the previous quarter ended on 9/29/2023 were -$1.41 per share as compared to estimates of -$1.52 per share, a difference of $0.11 representing a surprise of 7.20%.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Regenxbio Inc [NASDAQ:RGNX] is 2.57. Further, the Quick Ratio stands at 2.57, while the Cash Ratio is 0.26. Considering the valuation of this stock, the price to sales ratio is 11.20, the price to book ratio is 3.21.
Transactions by insiders
Recent insider trading involved PAKOLA STEVE, Chief Medical Officer, that happened on Mar 05 ’24 when 12878.0 shares were sold. President and CEO, Mills Kenneth T. completed a deal on Feb 14 ’24 to sell 15000.0 shares. Meanwhile, President and CEO Mills Kenneth T. sold 45000.0 shares on Jan 16 ’24.
